Company Overview of HUYA Bioscience International, LLC
HUYA Bioscience International, LLC engages in identifying and licensing pre-clinical and clinical stage compounds in China. It engages in accelerating the development of biopharmaceutical product opportunities originating in China. The company offers HBI-8000, a histone deacetylases inhibitors for cancer; HBI-3000, a multi-ion channel blocker for the treatment of arrhythmia; and HBI-3802, a small molecule for improving heart function, as well as stimulates cardiac stem cell differentiation into functional cardiomyocytes, and replaces and remodels dead myocardium with new functional tissues. The company has a strategic alliance with China Wuqing Development Area. HUYA Bioscience International...
12531 High Bluff Drive
San Diego, CA 92130
Founded in 2004
Key Executives for HUYA Bioscience International, LLC
Founder, Executive Chairman, Chief Executive Officer and President
Chief Technology Officer and Chief Operating Officer of Asia
Chief Scientific Officer and Executive Vice President
Head of Therapeutics China
Compensation as of Fiscal Year 2014.
HUYA Bioscience International, LLC Key Developments
HUYA Bioscience International Completes First Cohort in Phase 1 Clinical Trial of HBI-8000 in Japan
Mar 19 15
HUYA Bioscience International has completed the first cohort in a Phase 1 clinical trial in Japan of its cancer drug HBI-8000, a novel oral histone deacetylase inhibitor. This follows acceptance by the Pharmaceutical and Medical Devices Agency (PMDA) of the company's accelerated development strategy in Japan. The Phase 1 open-label, dose escalation trial is evaluating the safety and pharmacokinetics of HBI-8000 in Japanese patients with non `Hodgkin's lymphoma. The first cohort received HBI-8000 tablets twice weekly, with no dose-limiting toxicities observed. The second cohort is now underway with a higher dose. The trial is designed to establish a maximum tolerated dose (MTD) to proceed to Phase 2 trials for the treatment of adult T-cell leukemia/lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) in Japan. The clinical development of HBI-8000 in Japan leverages clinical data from Chinese clinical trials through the Tripartite Cooperation on Health between China, South Korea and Japan. Shenzhen Chipscreen Biosciences recently announced the approval of chidamide in China as the world's first oral HDAC inhibitor for the treatment of relapsed or refractory PTCL. HUYA holds exclusive rights to chidamide (HBI-8000) worldwide, excluding China, and is developing the compound for hematological malignancies and solid tumors.
HUYA Bioscience International, LLC Names Alain Rolland as Executive Vice President and Chief Scientific Officer
Mar 12 15
HUYA Bioscience International, LLC announced a key addition to its executive team. Alain Rolland, Pharm.D., Ph.D., has been appointed as Executive Vice President and Chief Scientific Officer. Dr. Rolland brings 25 years of international leadership experience in the biopharma industry, including positions at Ciba-Geigy, Galderma, GeneMedicine, Valentis, and Vical. Most recently, Dr. Rolland was a Corporate Officer and Executive Vice President of Product Development at Vical.
Huya Bioscience International Announces Joint Venture with Tianjin Institute of Pharmaceutical Research to Develop Medical Technologies and Therapies for Global Markets
Sep 16 14
Huya Bioscience International (US and China) has announced a joint venture with Tianjin Institute of Pharmaceutical Research (TIPR) to develop medical technologies and therapies for global markets. The joint venture will focus on developing China-sourced novel biopharmaceuticals for global markets. Under the agreement, Huya and TIPR will share the decision-making on product development and commercialisation equally and focus initially on the China market before also targeting international markets.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|